Mirati Therapeutics

265 articles with Mirati Therapeutics

• Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference

  3/6/2023

  Mirati Therapeutics, Inc. will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. / 9:00 a.m. E.T. 

• Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

  2/28/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates.

• Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference

  2/21/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the 43rd Annual Cowen Health Care Conference on March 6 at 11:10 a.m. P.T. / 2:10 p.m. E.T. 

• Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

  2/14/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.

• Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced that the company granted equity awards to 4 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• Mirati Therapeutics to Participate in Two Upcoming February 2023 Healthcare Conferences

  2/1/2023

  Mirati Therapeutics, Inc., a targeted oncology company, will participate in two upcoming healthcare conferences.

• Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

  1/19/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation.

• Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Jan 06, 2023

  1/6/2023

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  12/22/2022

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.

• Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

  12/21/2022

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.

• 

  Mirati Challenges Amgen in KRAS Space with FDA Accelerated Approval

  12/13/2022

  Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.

• Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - December 13, 2022

  12/13/2022

  Mirati Therapeutics, Inc. announced that the company granted equity awards to 11 new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

  12/12/2022

  Mirati Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for KRAZATI™, a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.

• 

  Mirati's KRAS Inhibitor Demonstrates Encouraging Clinical Profile in Latest Data Drop (Updated)

  12/6/2022

  Mirati's adagrasib demonstrated a solid safety profile in new data released Monday. Despite this, the company's stock fell 8% in after-hours trading.

• Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  12/5/2022

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups.

• 

  Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis

  12/2/2022

  Amid rampant buyout speculation, Mirati Therapeutics reported that it will continue its final analysis of the Phase III SAPPHIRE trial following an interim survival analysis.

• Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

  12/2/2022

  Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis.

• Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO

  11/28/2022

  Mirati Therapeutics, Inc. today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation.

• Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

  11/8/2022

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.

• Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

  11/8/2022

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer.